Professor Gerry Hanna is the Clinical Director for Oncology at the Northern Ireland Cancer Centre, Belfast City Hospital and holds honorary appointments at Queen’s University Belfast andosp the University of Melbourne and is the past Director of Radiation Oncology at the Peter MacCallum Cancer Centre in Melbourne.
Professor Hanna’s research interests are the use of PET/CT in radiotherapy planning for lung cancer, mechanisms of radiotherapy resistance, technical radiotherapy, stereotactic ablative radiotherapy and systemic therapy and immunotherapy combinations with radiotherapy. He is chief investigator of the International Atomic Energy Agency’s “PERTAIN” study and previous co-chief Investigator of the CONCORDE study, a UK study of novel agents in combination with radiotherapy in the treatment of lung cancer. He is a TMG member for the UK’s HALT, SARON and CONFIRM studies. He is a member of TROG and a prior member of the Australian National Particle therapy working group. Away from work he enjoys cycling, good music and pretending to play the piano.